öλÔÓéÀֵǼÈë¿ÚÏÂÔØ

µ¼Ê¦ÐÕÃû£º¹ù³Î
ÐÔ±ð£ºÄÐ
ÈËÆøÖ¸Êý£º547

ËùÊôԺУ£ºÉϺ£ÖÐÒ½Ò©´óѧ
ËùÊôԺϵ£ºÊеÚÁùÈËÃñÒ½Ôº
Ö°³Æ£º½ÌÊÚ
µ¼Ê¦ÀàÐÍ£º
ÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£ºÖÐҩѧ
Ñо¿ÁìÓò£º ÖÐÒ©ÁÙ´²Ò©ÀíÓ뿹Ö×ÁöÒ©ÎïÁÙ´²Ó¦Óᢡ¢´ú±íÐÔÂÛÖø£º¡¢(1)ChenPengguo£¬LiJie... [Õ¹¿ª]


Ñо¿ÁìÓò£º ÖÐÒ©ÁÙ´²Ò©ÀíÓ뿹Ö×ÁöÒ©ÎïÁÙ´²Ó¦Óᢡ¢´ú±íÐÔÂÛÖø£º¡¢(1)ChenPengguo£¬LiJie£¬HuoYan£¬LuJin£¬WanLili£¬YangQuanjun£¬HuangJinlu£¬GanRun£¬GuoCheng£¬Adenovirus-mediatedexpressionoforphannuclearreceptorNR4A2targetinghepaticstellatecellattenuatesliverfibrosisinrats£¬ScientificReports£¬2016£¬6£º33593¡¢(2)ChenPengguo£¬LiJie£¬HuoYan£¬LuJin£¬WanLili£¬LiBin£¬GanRun£¬GuoCheng£¬OrphannuclearreceptorNR4A2inhibitshepaticstellatecellproliferationthroughMAPKpathwayinliverfibrosis£¬PeerJ£¬2015£¬3£ºe1518¡¢(3)HuoYan£¬YiBing£¬ChenMing£¬WangNadan£¬ChenPengguo£¬GuoChengSunJianxin£¬InductionofNur77byhyperosideinhibitsvascularsmoothmusclecellproliferationandneointimalformation.£¬BiochemicalPharmacology£¬2014£¬92£¨4£©£º590~598¡¢(4)LiJie£¬LiXingxia£¬XuWeiheng£¬WangShaozhan£¬HuZhenlin£¬ZhangQing£¬DengXing£¬WangJing£¬ZhangJunping£¬GuoCheng£¬AntifibroticeffectsofluteolinonhepaticstellatecellsandliverfibrosisbytargetingAKT/mTOR/p70S6KandTGFbeta/Smadsignallingpathways.£¬LiverInternational£¬2015£¬35£¨4£©£º1222~1233¡¢(5)HuangJin-lu£¬HuoYan£¬WanLi-li£¬YangQuan-jun£¬LiJie£¬GuoCheng£¬CERKmightcontributetoinflammatorypain;CommentsonYuWL,Sun.Y(2015).CERKinhibitionmightbeagoodpotentialtherapeutictargetfordiseases.BrJPharmacol172:2165£¬BritishJournalofPharmacology£¬2016£¬173£¨7£©£º1248~1249¡¢(6)YangQuan-Jun£¬HuoYan£¬HanYong-Long£¬WanLi-Li£¬LiJie£¬HuangJin-Lu£¬LuJin£¬ChenPeng-Guo£¬GanRun£¬GuoCheng£¬SelumetinibattenuateskeletalmusclewastinginmurinecachexiamodelthroughERKinhibitionandAKTactivation£¬MolecularCancerTherapeutics£¬2017£¬16£¨2£©£º334~343¡¢(7)HanYong-Long£¬LiDan£¬YangQuan-Jun£¬ZhouZhi-Yong£¬LiuLi-Ya£¬LiBin£¬LuJin£¬GuoCheng£¬InVitroInhibitoryEffectsofScutellarinonSixHuman/RatCytochromeP450EnzymesandP-glycoprotein£¬Molecules£¬2014£¬19£¨5£©£º5748~5760¡¢(8)LiuLi-Ya£¬HanYong-Long£¬ZhuJin-Hui£¬YuQi£¬YangQuan-Jun£¬LuJin£¬GuoCheng£¬Asensitiveandhigh-throughputLC-MS/MSmethodforinhibitionassayofsevenmajorcytochromeP450sinhumanlivermicrosomesusinganinvitrococktailofprobesubstrates.£¬BiomedicalChromatography£¬2015£¬29£¨3£©£º437~444¡¢(9)QuanJunYang£¬GenJinYang£¬LiLiWan£¬YongLongHan£¬YanHuo£¬£¬JieLiJinLuHuang£¬JinLu£¬RunGan£¬ChengGuo£¬ProtectiveEffectsofDexrazoxaneagainstDoxorubicin-InducedCardiotoxicity:AMetabolomicStudy.£¬PLosOne£¬2017£¬12£¨1£©£ºe**¡¢(10)YangQuanJun£¬YangGenJin£¬WanLiLi£¬HuoYan£¬HanYongLong£¬LuJin£¬LiJie£¬HuangJinLu£¬GuoCheng£¬Integratedanalysisofserumandintactmusclemetabonomicsidentifymetabolicprofilesofcancercachexiainadynamicmousemodel£¬RSCAdvances£¬2015£¬5£¨112£©£º92438~92448¡¢(11)QuanJunYang£¬JunBian£¬LiiWan£¬YonglongHan£¬BinLi£¬QiYu£¬YanLi£¬ChengGuo£¬GenjinYang£¬NMR-BasedMetabolomicsRevealsDistinctPathwaysMediatedbyCurcumininCachexiaMiceBearingCT26Tumor£¬RSCAdvances£¬2015£¬5£¨1£©£º11766~11775¡¢(12)YangQuanjun£¬ZhangJianping£¬ZhangJianhua£¬HanYonglong£¬XinBo£¬ZhangJingxian£¬DaiBona£¬ZhangYuan,DistinctMetabolicGuoChengProfileofInhaledBudesonideandSalbutamolinAsthmaticChildrenduringAcuteExacerbation£¬BasicClinPharmacolToxicol£¬2017£¬120£¨3£©£º303~311¡¢(13)LiBin£¬WanLili£¬LiYan£¬YuQi£¬ChenPengguo£¬GanRun£¬YangQuanjun£¬HanYonglong£¬GuoCheng£¬Baicalin,acomponentofScutellariabaicalensis,alleviatesanorexiaandinhibitsskeletalmuscleatrophyinexperimentalcancercachexia£¬TumorBiology£¬2014£¬35£¨12£©£º12415~12425¡¢(14)Zhou,Zhiyong£¬Wan,Lili£¬Han,Yonglong£¬Meng,Xiangle£¬Yang,Quanjun£¬Li,Yan£¬Yu,Qi£¬Shen,Zan£¬Guo,Cheng£¬ABCB1-overexpressingMG63/DOXcellxenograftmodel:MaintaintheMDRphenotypeinvivo£¬PHARMACEUTICALBIOLOGY£¬2013£¬51£¨8£©£º968~973¡¢(15)YangQuanjun£¬WanLili£¬ZhouZhiyong£¬LiYan£¬YuQi£¬LiuLiya£¬LiBin£¬GuoCheng£¬ParthenolidefromPartheniumintegrifoliumreducestumorburdenandalleviatecachexiasymptomsinthemurineCT-26modelofcolorectalcarcinoma£¬PHYTOMEDICINE£¬2013£¬20£¨11£©£º992~998¡¢(16)WanLili£¬SunYehong£¬YuQi£¬HuoYan£¬ZhuJinhui£¬LiYan£¬GuoCheng£¬Invitropermeabilityanalysis,pharmacokineticandbraindistributionstudyinmiceofimperatorin,isoimperatorinandcnidilininRadixAngelicaeDahuricae£¬FITOTERAPIA£¬2013£¬85£º144~153¡¢(17)Quanjun,Yang£¬Genjin,Yang£¬Lili,Wan£¬Bin,Li£¬Jin,Lu£¬Qi,Yu£¬Yan,Li£¬Yonglong,Han£¬Cheng,Guo£¬Junping,Zhang£¬Serummetabolicprofilesrevealtheeffectofformoteroloncachexiaintumor-bearingmice.£¬MolBiosyst£¬2013£¬9£¨12£©£º3015~3025¡¢(18)LiliWan£¬£¬ZhiyongZhou£¬QiYu£¬YanLi£¬DanLi£¬XueliChengGuoZheng£¬YuanZhong£¬Steady-stateplasmaconcentrationofdonepezilenantiomersanditsstereoselectivemetabolismandtransportinvitro.£¬Chirality£¬2013£¬25£¨9£©£º498~505¡¢(19)ZhouZhi-yong£¬WanLi-li£¬YangQuan-jun£¬HanYong-long£¬LiYan£¬YuQi£¬GuoCheng£¬LiXiao£¬Evaluationofthepharmacokineticsandcardiotoxicityofdoxorubicininratreceivingnilotinib£¬ToxicologyandAppliedPharmacology£¬2013£¬272£¨1£©£º238~244¡¢(20)LiBin£¬WanLili£¬LiYan£¬YuQi£¬ChenPengguo£¬GanRun£¬YangQuanjun£¬HanYonglong£¬GuoCheng£¬Baicalin,acomponentofScutellariabaicalensis,alleviatesanorexiaandinhibitsskeletalmuscleatrophyinexperimentalcancercachexia.£¬TumorBiology£¬2013£¬35£¨12£©£º12415~12425¡¢(21)Li,Bin£¬Gan,Run£¬Yang,Quanjun£¬Huang,Jinlu£¬Chen,Pengguo£¬Wan,Lili£¬Guo,Cheng£¬ChineseHerbalMedicinesasanAdjunctiveTherapyforUnresectablePancreaticCancer:ASystematicReviewandMeta-Analysis£¬Evidence-BasedComplementaryandAlternativeMedicine£¬2015£¬350730¡¢(22)LuJin£¬FuJianliang£¬ZhongYuan£¬ChenPengguo£¬YangQuanjun£¬ZhaoYuwu£¬WanLili£¬£¬TherolesofapolipoproteinE3andGuoChengCYP2D6(rs**)genepolymorphismsinthepredictabilityofresponsestoindividualizedtherapywithdonepezilinHanChinesepatientswithAlzheimer'sdisease£¬NeuroscienceLetters£¬2016£¬614£º43~48¡¢(23)ZhouZhi-yong£¬WanLi-li£¬YangQuan-jun£¬HanYong-long£¬LiDan£¬LuJin£¬GuoCheng£¬NilotinibreversesABCB1/P-glycoprotein-mediatedmultidrugresistancebutincreasescardiotoxicityofdoxorubicininaMDRxenograftmodel£¬ToxicologyLetters£¬2016£¬259£º124~132¡¢¡¢ [ÊÕÆð]




ͨѶ·½Ê½ :
°ì¹«µç»°£º**
µç×ÓÓʼþ£ºgboss@126.com
ͨѶµØÖ·£ºÉϺ£ÊÐÒËɽ·600ºÅ


¸öÈ˼òÊö :
2012Ä꡶»ùÓÚϸ°ûÉ«ËØP450øϵµÄ³£ÓÃÖÐÒ©´úлÐÔÏ໥×÷ÓÃÑо¿¡·»ñµÃÉϺ£Ò½Ñ§¿Æ¼¼½±ÈýµÈ½±¡£

2014Äê¹ù³ÎÖ÷ÈÎǣͷµÄ¡¶³£ÓÃÖÐÒ©¼°ÆäÓÐЧ³É·ÖµÄ´úлÐÔÒ©ÎïÏ໥×÷ÓÃÑо¿¡·»ñµÃÉϺ£ÖÐÎ÷Ò½½áºÏ¿Æѧ¼¼Êõ½±Ò»µÈ½±


¿ÆÑй¤×÷ :
2005/1-ÖÁ½ñ£¬ÉϺ£½»Í¨´óѧ¸½ÊôµÚÁùÈËÃñÒ½Ôº£¬Ò©¼Á¿Æ£¬Ö÷ÈÎҩʦ

2001/8-2004/12£¬µÚ¶þ¾üÒ½´óѧ¸½Êô³¤Õ÷Ò½Ôº£¬Ò©²Ä¿Æ£¬Ö÷ÈÎҩʦ

1996/7-2001/7£¬µÚ¶þ¾üÒ½´óѧ¸½Êô³¤Õ÷Ò½Ôº£¬Ò©²Ä¿Æ£¬¸±Ö÷ÈÎҩʦ

1993/7-1996/7£¬µÚ¶þ¾üÒ½´óѧ¸½Êô³¤Õ÷Ò½Ôº£¬Ò©²Ä¿Æ£¬Ö÷¹Üҩʦ
¦Â2-AR¼¤¶¯¼Á¸£ÄªÌØÂÞµ÷¿ØBCKDC¸ÄÉƶñ²¡ÖʹÇ÷À¼¡Î®ËõµÄ×÷ÓûúÖÆÑо¿

ÐòºÅ¿ÎÌâÃû³ÆÑо¿Æðֹʱ¼ä¾­·ÑÊý(ÍòÔª)±¸×¢1ERK5/MAPK ÐźÅͨ·ÔÚ¸ÎÏËά»¯ÖеÄ×÷Óü°Ä¾Ï¬²ÝËØ¿¹¸ÎÏËά»¯µÄ×÷ÓûúÖƵÄÑо¿2011/01-2013/1232ÒѽáÌâ22015/01-2017/1217.932016ÄêÉϺ£ÊÐÁÙ´²Ò©Ñ§Öصãר¿Æ½¨ÉèÏîÄ¿2016.9-2018.8100

½ÌÓý±³¾° :
1990/9¨C1993/7£¬ µÚ¶þ¾üÒ½´óѧ£¬ ҩѧ£¬ ²©Ê¿£¬ µ¼Ê¦£ºËÕÖÐÎä

1987/9¨C1990/7£¬ µÚ¶þ¾üÒ½´óѧ£¬ ҩѧ£¬ ˶ʿ£¬ µ¼Ê¦£ºËÕÖÐÎä

1983/9¨C1987/7£¬ µÚ¶þ¾üÒ½´óѧ£¬ ҩѧ£¬ ѧʿ